TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03618966

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular magnetic stimulation (NMMS)
Description: It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular magnetic stimulation (NMMS)
Description: It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.
Study: NCT01797419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5806
Description: Single dose, oral liquid, .5 mL/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, oral liquid, .5 mL/kg
Study: NCT03154333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diacerein 1% ointment
Description: diacerein 1% ointment administered topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A placebo ointment
Description: vehicle ointment administered topically
Study: NCT00618969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: haploidentical allogeneic PBSC transp
Description: Days -5 and -4: IV busulfan 3.2 mg/kg/dose daily for 2 days~Day -3: IV melphalan 100 mg/m2 as a single dose~Days -2 and -1: IV alemtuzumab 30 mg/dose daily for 2 days~Day 0: Transplantation of haploidentical related allogeneic peripheral blood stem cells (PBSCs)- target cell dose 10 x 106 donor CD34+ cells per kilogram of recipient weight
Study: NCT03057119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting (5 minutes)
Description: The interventionist will use motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identifying and prioritizing needs (5 minutes)
Description: The interventionist will use problem-solving techniques to help patients identify which services may best help them work towards their goals. Services will include (but are not limited to) emergency crisis services, counseling to deal with substance use, referral to local self-help groups (Alcoholics Anonymous, Narcotics Anonymous, etc.), legal assistance, faith-based counseling, mental health counseling or inpatient substance use treatment.
Study: NCT01672372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Max Stress B
Description: Participants are to mix one vial per day of either placebo or actual supplement in 1 liter of water and drink over the course of the day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Max Stress B
Study: NCT04316052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: After the baseline assessment, Following randomization into the exercise group, participants will undergo an exercise program orientation, which will be conducted individually.At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine. Participants will be instructed to walk for 45 minutes, including a 5-minute warm-up and 5 min cool-down, at 50% to 80% of their age-predicted maximum heart rate.Over the course of 4 months, each patient will complete 48 sessions. The morning after the 24th and 48nd sessions of aerobic physical exercise, each participant will be assessed completely

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strength training
Description: After the baseline assessment, participants will undergo exercise program orientation, which will be conducted individually. Participants will be instructed to perform 45 min session, two sets of 8 to 12 repetitions of each exercise (2 second hold each up and down hold) for the first 2 weeks to provide an introductory period. In the first session, muscular strength will be assessed using a standardized 10-repetition maximum approach, from which one repetition maximum (1-RM) will be estimated. The exercise prescription for strength training will be made at approximately 50% of the estimated 1-RM.The strength training activities included horizontal leg press, leg extension, leg curl, hip adduction, hip abduction, and seated rotary calf press.
Study: NCT04852991

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Purandare cervicopexy
Description: The modified Purandare's cervicopexy will be performed in low lithotomy position . Pfannenstiel incision was utilized and the abdomen was opened in layers maintaining perfect hemostasis. Uterus will be delivered through the incision and held with uterus holding forceps. The bladder was dissected inferiorly. A 25-30 cm long strip of polypropylene mesh was prepared by soaking. The mesh was fixed anteriorly at the level of isthmus by No.1 polypropylene sutures . The ends of the mesh were brought lateral to rectus muscle retroperitoneally on both sides taking care not to injure the inferior epigastric vessels. After confirming the correct fixation and haemostasis the uterovesical fold of peritoneum was approximated. The ends of the mesh were fixed to the rectus muscle by criss crossing using No. 1 polypropylene sutures. After confirming the haemostasis, the abdomen was closed in layers. Per speculum examination was done to note the reduction of prolapse.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal sacral hysteropexy
Description: After peritoneal entry through pfannenstiel incision was, the bladder is mobilized off the cervix. Windows are made in the broad ligament at the level of the isthmus. Posteriorly, the rectovaginal space is entered at the level of the uterosacral ligaments. Next, a 15x15-cm polypropylene mesh is used to fashion two 4.5- to 5-cm-wide strips of mesh; one is bisected for a distance of 5 cm to produce a Y-configuration for the anterior mesh.The anterior mesh arms are passed through the broad ligament windows and attached to the cervix and pubocervical fascia using interrupted 2-0 PDS. The posterior mesh is attached to the rectovaginal fascia using transverse-interrupted 2-0 PDS sutures. Once the sacral dissection has exposed the anterior longitudinal ligament, the proximal ends of the 2 mesh strips are attached to the sacral promontory using two 2-0 polyester sutures to provide elevation of the uterus without tension. The peritoneum is closed over the mesh using a 3-0 vicryl suture
Study: NCT01260571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide and sulfur
Description: topical cream, 5% benzoyl peroxide and 2% sulfur Frequency once to day Duration 24 hours
Study: NCT01710306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Care Manager (NCM)
Description: Nurse care manager interventions with telephone implemented shared decision making protocol compared to outreach as usual OEF/OIF/OND outreach.
Study: NCT01512979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 1000 mg to 2000 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: 5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: 5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin placebo
Description: 0 to 2 tablets daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin placebo
Description: 4 tablets daily
Study: NCT04684810

Intervention type: BEHAVIORAL
Intervention: Community Lay Therapist-Administered EBT
Description: Community Therapists Used CBT and EMDR Interventions
Study: NCT00936884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; 0.4 mL (8 mg) every other day if weight between 38 and \< 62 kg; or 0.0075 mL/kg (0.15 mg/kg) every other day if weight between 27 and \<38 kg.~Study duration: 2 weeks double-blind period (MNTX treatments) followed by 12 weeks open-label extension period (MNTX treatments).

Intervention type: DRUG
Group type: OTHER
Intervention: Methylnaltrexone
Description: Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; 0.4 mL (8 mg) every other day if weight between 38 and \< 62 kg; or 0.0075 mL/kg (0.15 mg/kg) every other day if weight between 27 and \<38 kg.~Study duration: 2 weeks double-blind period (MNTX treatments) followed by 12 weeks open-label extension period (MNTX treatments).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received matching placebo injections.~Study duration: 2 weeks double-blind period (placebo treatments) followed by 12 weeks open-label extension period (MNTX treatments).
Study: NCT02557672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (Human)
Description: PCC (Kcentra)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Description: FFP
Study: NCT02378506

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: 50mg subcutaneous, once weekly, 24 weeks
Study: NCT02123459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Administered orally
Study: NCT01377233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine open-label lead-in 10 mg daily
Description: Encapsulated tablet ,10 mg, once daily, open-label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine 10 mg daily
Description: Encapsulated tablet, 10 mg, once daily, double-blind

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine 20 mg once weekly
Description: Encapsulated tablet, 20 mg, once weekly (on day 1 of each 7 day cycle), double-blind

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine 30 mg once weekly
Description: Encapsulated tablet, 30 mg, once weekly (on day 1 of each 7 day cycle), double-blind

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine 45 mg once weekly
Description: Encapsulated tablet, 45 mg, once weekly (on day 1 of each 7 day cycle), double-blind
Study: NCT04303052

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiodynamic Bioflo Picc IR-KIT (145 cm guidewire) or
Description: Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiodynamic Bioflo Picc MST-KIT (70 cm guidewire)
Description: Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
Study: NCT00609778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUCAS
Description: Mechanical chest compression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional manual resuscitation method
Description: Manual compression
Study: NCT04929197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PERSBRA
Description: After the patient is in the semi-prone position, the body shape and breast position images are obtained by the stereo scanning technology, and then using 3d printing technology to print PERSBRA.~PERSBRA maintain a favorable new breast position in the supine position during routine radiotherapy, the cardiopulmonary dose during radiotherapy can be reduced by wearing PERSBRA.
Study: NCT02948478

Intervention type: OTHER
Intervention: Exposed
Description: Precarious patients

Intervention type: OTHER
Intervention: Non exposed
Description: Non precarious patients
Study: NCT03058939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.

Intervention type: DRUG
Group type: OTHER
Intervention: Perjeta
Description: Only administered to patients with HER2-positive disease.

Intervention type: DRUG
Group type: OTHER
Intervention: Herceptin SC
Description: Only administered to patients with HER2-positive disease.

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Description: Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.

Intervention type: DRUG
Group type: OTHER
Intervention: LHRH agonist
Description: Administered to all premenopausal patients.

Intervention type: DRUG
Group type: OTHER
Intervention: FEC
Description: Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
Study: NCT03057119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explanation of Peer Navigator and Session wrap (5 minutes)
Description: The interventionist will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
Study: NCT00377819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate
Description: 70 mg oral QW
Study: NCT03916237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home assessment
Description: Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home assessment
Description: Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home assessment
Description: Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)
Study: NCT00377819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (AMG 162)
Description: 60 mg SC q 6 mos
Study: NCT01278277

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saffron supplementation
Description: Saffron supplementation 20 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo supplementation
Study: NCT03830034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acid chelated iron tab 15 mg
Description: Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) a dose recommended by the company of the product.~Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
Description: 75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb\<9g/dl) this dose can be doubled as recommended by the company of the product.~Some instructions will be given to all the pregnant women included in our study as follow: Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed.
Study: NCT03546244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical treadmill
Description: Patients will undergo a 4-week, 2 daily, incremental session of training with musical treadmill

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treadmill
Description: Patients will undergo a 4-week, 2 daily, incremental session of training with traditional treadmill
Study: NCT01504594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous stem cell infusion
Description: Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.
Study: NCT05331352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Description: Interview

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Description: Interview

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Projective methode
Description: Rorschach + thematic aperception test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Projective methode
Description: Rorschach + thematic aperception test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Selfreported
Description: RSQ - PBI - RFQ - QSCPGS - SSQ6 - ÉCHELLES DE CUNGI - STAI - PCL-S - IES-R

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Selfreported
Description: RSQ - PBI - RFQ - QSCPGS - SSQ6 - ÉCHELLES DE CUNGI - STAI - PCL-S - IES-R
Study: NCT01466998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paced Respiration
Description: Practice paced respiration 15 minutes per day for a total of 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy
Description: Practice music therapy for 15 minutes per day for a total of 12 weeks.
Study: NCT03475108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Worker added to diabetes team
Description: A Community Health Worker will be added to the diabetes team caring for a child with type 1 diabetes over 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.

Intervention type: OTHER
Group type: OTHER
Intervention: Community Health Worker added to diabetes team
Description: A Community Health Worker will be added to the diabetes team caring for a child with type 1 diabetes over 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
Study: NCT03455426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Women will be randomizedfor ovarian stimulation with letrozole or to natural cycle IUI.
Study: NCT00321919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta [NeoRecormon]
Description: Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin beta [NeoRecormon]
Description: Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to \<10.5 g/dL had occurred.
Study: NCT02768142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural cesarean delivery
Description: Natural cesarean delivery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard cesarean delivery
Description: Standard cesarean delivery
Study: NCT03387059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forielle
Description: Participants randomized to receive Forielle endometrial washing (an intrauterine solution) following oocyte retrieval on Study Day 0 (Randomisation).
Study: NCT01337154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Tablet, 6 mg/m2, oral, divided into twice a day dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, orally, daily